SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma’s arm gets marketing authorization for four products

02 Jul 2024 Evaluate

Marksans Pharma’s wholly owned subsidiary – Relonchem has received marketing authorization from UKMHRA for Rasagiline Relonchem 1 mg Tablets, Olmesartan 10 mg Film-coated Tablets, Olmesartan 20 mg Film-coated Tablets and Olmesartan 40 mg Film-coated Tablets. 

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma Share Price

270.00 0.50 (0.19%)
14-Jul-2026 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1943.70
Dr. Reddys Labs. 1243.45
Cipla 1445.95
Zydus Lifesciences 1138.25
Lupin 2474.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: